News Search Results
Feb 04, 2026, 07:48 ET AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results
therapy in lymphoma. Epkinly is being co-developed by AbbVie and Genmab. AbbVie announced topline results from the Phase 3 EPCORE DLBCL-1 trial evaluating Epkinly compared to investigator's choice of chemoimmunotherapy in adult patients with R/R diffuse large B-cell lymphoma (DLBCL).
More news about: AbbVie
Feb 03, 2026, 08:50 ET Allergan Aesthetics Continues Its Mission of Empowering Women Through the Faces of Natrelle® Testimonial Program
surgery.Breast implants have been associated with the development of a cancer of the immune system called breast implant–associated anaplastic large cell lymphoma (BIA-ALCL). This cancer occurs more commonly in patients with textured breast implants than smooth implants, although rates are not well defined.
More news about: AbbVie
Feb 03, 2026, 08:00 ET AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Adults and Adolescents With Vitiligo
immune system problems. RINVOQ may increase your risk of certain cancers. Lymphoma and other cancers, including skin cancers, can happen. Current or past smokers are at higher risk of certain cancers, including lymphoma and lung cancer. Follow your HCP's advice about having your skin checked for skin
More news about: AbbVie
Feb 02, 2026, 16:05 ET Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit
More news about: Karyopharm Therapeutics Inc.
Feb 02, 2026, 16:05 ET ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy.Headquartered
More news about: ADC Therapeutics SA
Feb 02, 2026, 11:37 ET AMERICAN SKIN ASSOCIATION ANNOUNCES APPOINTMENT OF PATRICK M. BRUNNER, MD, MSC TO MEDICAL ADVISORY COMMITTEE
Dr. Brunner serves as Associate Professor of Dermatology and Director of the Cutaneous Lymphoma Clinic in the Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai. His research connects sophisticated
More news about: American Skin Association
Jan 30, 2026, 10:36 ET $170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium
topline results from the Phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab in adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The study demonstrated improvement in progression-free survival with a hazard ratio of 0.74, along with improvements in complete response
More news about: Equity Insider
Jan 30, 2026, 08:00 ET Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)
clinical trials involving paxalisib are ongoing in advanced breast cancer, brain metastases, diffuse midline gliomas, and primary central nervous system lymphoma, with several of these trials having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation for glioblastoma by the U.S.
More news about: Kazia Therapeutics Limited
Jan 29, 2026, 09:00 ET GIVEBYCRUISING PARTNERS WITH BLOOD CANCER UNITED TO ADVANCE BLOOD CANCER RESEARCH
Jan. 29, 2026 /PRNewswire/ -- GiveByCruising by Dream Vacations is proudly partnering with Blood Cancer United® (formerly The Leukemia & Lymphoma Society) to fund critical blood cancer research. The full-service travel agency will donate 70% of its booking commissions over the next five years
More news about: BLOOD CANCER UNITED, INC.
Jan 28, 2026, 17:31 ET DUB Inhibitors Market to Witness Strong Expansion Across 7MM by 2040 Driven by the Launch of Novel Therapeutics | DelveInsight
treatment practices, addressable patient population, which includes top indications such as Heart Failure, Parkinson's Disease, Alzheimer's Disease, Lymphoma, Breast Cancer, and others. The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides insights
More news about: DelveInsight Business Research, LLP
Jan 27, 2026, 08:00 ET Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer
clinical trials involving paxalisib are ongoing in advanced breast cancer, brain metastases, diffuse midline gliomas, and primary central nervous system lymphoma, with several of these trials having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation for glioblastoma by the U.S.
More news about: Kazia Therapeutics Limited
Jan 22, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
ZYNLONTA® in combination with the bispecific antibody glofitamab (COLUMVI®) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL)." Although the press release described the data in positive terms, the press release reported that adverse events occurred in two patients,
More news about: Pomerantz LLP
Jan 21, 2026, 03:07 ET Kanazawa University research: Visualizing how cancer drugs reshape proteins linked to lung cancer
Reference High-Speed Atomic Force Microscopy Reveals Disordered Region–Mediated Structural Plasticity of Anaplastic Lymphoma Kinase Fusion Proteins Induced by Inhibitors, Xujun Han, Noriyuki Kodera, Neval Yilmaz, Katsuya Sakai, Sachiko Arai, Borui Li, Ryu
More news about: Kanazawa University
Jan 16, 2026, 13:43 ET AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Kanas, et al. Epidemiology of Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL) in the United States and Western Europe: Population-Level Projections for 2020-2025. Leuk Lymphoma. 2022;63(1):54-63. doi: 10.1080/10428194.2021.1975188.
More news about: AbbVie
Jan 15, 2026, 17:31 ET Hemophagocytic Lymphohistiocytosis Market Poised for Phenomenal Expansion in the US at a CAGR of 24.5% During the Forecast Period (2025-2034) | DelveInsight
current hemophagocytic lymphohistiocytosis patient pool and forecasted trends for the leading markets. The commonest single disease entities were lymphoma, SLE, and sJIA. There has been evidence of clinically diagnosed HIV, EBV, or CMV infection either in the health record or on the death certificate
More news about: DelveInsight Business Research, LLP
Jan 15, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
efficacy of ZYNLONTA® in combination with the bispecific antibody glofitamab (COLUMVI®) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL)." Although the press release described the data in positive terms, the press release reported that adverse events occurred in two patients,
More news about: Pomerantz LLP
Jan 14, 2026, 10:45 ET AVEO Oncology, an LG Chem company, Announces First Patient Dosed in Front-Line AML Combination Study of Ficlatuzumab
acute myeloid leukemia (AML) through a Master Clinical Trial Collaboration Agreement with Blood Cancer United®, formerly the Leukemia & Lymphoma Society.
More news about: AVEO, an LG Chem company
Jan 14, 2026, 09:00 ET High School Students Nationwide Kick off Philanthropic Competition to Help All Blood Cancer Patients Live Longer, Better Lives
WASHINGTON, Jan. 14, 2026 /PRNewswire/ -- Blood Cancer United®, formerly The Leukemia & Lymphoma Society, is proud to kick-off its annual iconic philanthropic competition,
More news about: BLOOD CANCER UNITED, INC.
Jan 14, 2026, 08:00 ET Blood Cancer United Expands its Beat AML® Master Clinical Trial Advancing Next-Generation Treatment
WASHINGTON, Jan. 14, 2026 /PRNewswire/ -- Blood Cancer United®, formerly The Leukemia & Lymphoma Society, announced today that the first patient has received treatment in a new sub-study of its Beat AML® Master Clinical Trial (Beat AML).
More news about: Blood Cancer United® formerly The Leukemia & Lymphoma Society
Jan 13, 2026, 13:05 ET Entrepreneur Names Urban Air No. 1 Adventure Park Brand in 2026 Franchise 500® for Eighth Consecutive Year
to raise money and awareness during National Childhood Cancer Awareness Month in partnership with Blood Cancer United (formerly The Leukemia & Lymphoma Society."Urban Air continues to be the go-to choice for families across the country, offering one-of-a-kind experiences that bring communities
More news about: Urban Air Adventure Park
Jan 13, 2026, 09:00 ET Vector Solutions Marks Firefighter Cancer Awareness Month with Expanded Training and Education
reduce occupational cancer risks.Firefighters face elevated risks for several cancers, including skin melanoma, prostate cancer, non-Hodgkin lymphoma, and testicular cancer, underscoring the importance of standards-aligned, ongoing education."Firefighter health and safety has always been core
More news about: Vector Solutions
Jan 13, 2026, 08:25 ET David Arquette Teams Up With Colossal to Find America's Most Artistic Kid in an Online Fundraising Competition Benefiting Blood Cancer United
Blood Cancer United. Formerly the Leukemia & Lymphoma Society, this incredible organization aims to cure blood cancer and enhance the quality of life for patients and their families.This Colossal
More news about: Colossal
Jan 12, 2026, 08:00 ET Florida Cancer Specialists & Research Institute Expands Clinical Team in Lake County, Welcomes Aamir Hussain to Statewide Practice
Clermont, FL 34711 and in Tavares, 4100 Waterman Way, Tavares, FL 32778. Dr. Hussain has special interest in prostate cancer, breast cancer, and lymphoma.
More news about: Florida Cancer Specialists & Research Institute
Jan 12, 2026, 07:00 ET Karyopharm Announces Preliminary Unaudited 2025 Revenue and Reiterates Expectation of Delivering Potentially Transformative Phase 3 Data in 2026
heavily pre-treated multiple myeloma; and (iii) under accelerated approval in adult patients with diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy. XPOVIO® (also known as NEXPOVIO® in certain countries) has received regulatory
More news about: Karyopharm Therapeutics Inc.
Jan 09, 2026, 08:00 ET Curis Announces Closing of Private Placement Totaling up to $80.8 Million in Gross Proceeds
inhibitor. Emavusertib is currently being evaluated in the TakeAim Lymphoma Phase 1/2 study (CA-4948-101) of emavusertib in combination with the BTK inhibitor ibrutinib in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) and in a Phase 2 study (CA-4948-203) of emavusertib in
More news about: Curis, Inc.